Dr. Antoni Chan
2 years 9 months ago
Crude drug retention at 1 year was 65% for JAKi, significantly lower than for other modes of action (74%) and TNFi (77%). These results are driven by the severity of the disease of patients on JAKi compared to other MOA. Aymon R Abst#1692 #ACR23 @RheumNow https://t.co/LPDpWdjoLg https://t.co/Ztaz94omd9
Mike Putman EBRheum
2 years 9 months ago
Obs study, bDMARDs & malignancy
TNFi w/lower risk than ABA/RTX/IL6i & numerically lower than JAKs
I'm a little skeptical... KM curves diverged w/~45 days, seems implausible?
Agree w/first author, possible channeling bias
@RheumNow #ACR23 Abstr 1678 https://t.co/1uL3j6kTSj
Richard Conway
2 years 9 months ago
Sendaydiego et al. Comparative cancer safety b/tsDMARDs. 37,026 patient database cohort study. Compared to TNFi, RTX HR 2.2 (1.5, 3.3) ABA HR 1.7 (1.3-2.4), JAKi HR 1.3 (0.9-1.9). Abstr#1678 #ACR23 @RheumNow https://t.co/bTNtaNJrln https://t.co/qQBM2F2q8N
Aurelie Najm
2 years 9 months ago
Ritux (OR 2.2), ABA (OR 1.3), JAKi (OR 1.3) significantly increase risk of cancer vs. TNFi
Cohort of 37000+ RA pts starting bio/tsDMARDs (379 incident cancers)
True biologic effect or confounding by indication in a generally more comorbid population?
@RheumNow #ACR23 ABST1678 https://t.co/suj6mVBEC0
Md Yuzaiful Md Yusof
2 years 9 months ago
#ACR23 Abstr#0840 Could combined JAK1/Tyk2 fare better than Tofacitinib in D2T #RA? Phase 2 RCT showed impressive results; > %50 pts in the higher doses TLL-018 arms achieved ACR50 vs TOF (42%). TOF non-responders at WK12 who switched to TLL-018 improved too @RheumNow #ACRBest https://t.co/Yw6Pvb2PH8
TheDaoIndex KDAO2011
2 years 9 months ago
Abst #1584 TMP-SMX⬇️PJP ⬇️SIE,⬇️outpt infx in GPA on RTX. 919 patients: 31% had TMP-SMX, 40% on pred >20 mg/day followed median 496 days. SIE (aHR 0.5, 95%CI 0.3-0.8), outpt infx (aHR 0.7, 95%CI 0.5-0.9), & PJP. Thirteen PJP (all not on TMP-SMX). #ACRbest #ACR23 @rheumnow
Dr. John Cush RheumNow
2 years 9 months ago
Starting soon! Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/xIBJlYCMQM
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more.
Dr. John Cush RheumNow
2 years 9 months ago
RheumNow’s expanded coverage of the #ACR23 is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Eric Dein
2 years 9 months ago
A#1486 @RheumNow #ACR23
STEMI outcomes - SLE v non-SLE
1,000,000 STEMIs, 4000 (0.4% SLE pts)
Younger age in SLE grp 61 v 67 yo
Increased risk of mortality: aOR 1.3 (CI 1.1-1.5, p<0.05)
LOS increased 4.7 v 4.5 d, increased hosp $
SLE: risk of CVD & worse prognostic effect
Dr. Antoni Chan
2 years 9 months ago
Trimethoprim sulfamethoxazole (TMP-SMX) negatively associated with serious infections. Rates for adverse events possibly attributable to TMP-SMX per 100 person-years were 29.6 during and 13.4 post exposure. Mendel A, Abst#1584 #ACR23 #ACRBest @RheumNow https://t.co/hHY2bZXrkS https://t.co/2YMoCi1zrx
Richard Conway
2 years 9 months ago
Eder et al. Women with PsA have worse outcomes with advanced therapies. OR favours men for ACR 20, IL-17i (OR 1.76), IL-23i (OR 1.46), IL-12/23i (OR 2.66) and TNFi (OR 1.67). Maybe not JAKi (OR 1.09). Placebo OR 1.04. Abstr#1687 #ACR23 @RheumNow https://t.co/bkDmmmYECF https://t.co/VBLnJzhcaY
Eric Dein
2 years 9 months ago
PAPILUP: HPV in SLE
A#1479 #ACR23 @RheumNow
65 SLE pts v healthy v HIV+
45% not up to date, one only HPV vax
High risk HPV in 29% SLE pts, similar to gen pop
BUT multiple HR-HPV +abnml cytology higher 15% v 7%, similar to HIV+
Clearance impaired on GCs
RF: lupus duration
#ACRBest
